Bronchiectasis Medical Slides
Generate publication-quality bronchiectasis lecture slides in 30 seconds. AI-powered content structured for clinical education.
Generate Bronchiectasis DeckWhy teach Bronchiectasis?
Bronchiectasis prevalence has increased by 40% over the past decade, affecting approximately 350-566 per 100,000 adults. Post-infectious causes remain most common globally, though idiopathic bronchiectasis accounts for 30-50% of cases in developed countries. The 2017 ERS guidelines provide the framework for etiological workup, and the Bronchiectasis Severity Index (BSI) guides risk stratification and management intensity.
What AI generates for Bronchiectasis
Enter “Bronchiectasis” and SlideCraft generates a complete lecture deck with slides like these.
See it in action
Type any medical topic and watch AI generate a presentation slide in seconds. No signup required.
3 free previews per hour · No account needed
Enter a topic and click Generate to see your AI slide
Bronchiectasis Presentation FAQ
What etiological workup should be presented in bronchiectasis teaching?
Present the ERS 2017 minimum workup: immunoglobulins (IgG, IgA, IgM — immunodeficiency in 2-8%), specific antibody responses, ABPA screen (total IgE, Aspergillus-specific IgE/IgG — ABPA in 1-10%), sputum culture (including mycobacteria), and consider: CF testing (sweat chloride + CFTR genetics, especially if age <40), alpha-1 antitrypsin level, ciliary function testing, autoimmune panel. Up to 30-50% remain idiopathic despite comprehensive evaluation.
How should long-term macrolide evidence be presented?
Present the three landmark trials: EMBRACE (azithromycin 500 mg 3x/week reduced exacerbations, NZ), BAT (azithromycin 250 mg daily reduced exacerbations by 70%, Netherlands), BLESS (erythromycin 400 mg twice daily reduced exacerbations, Australia). Common findings: approximately 50% reduction in exacerbation frequency. Key considerations: screen for NTM before starting (risk of macrolide resistance), ECG for QTc prolongation, hearing assessment, liver function monitoring. ERS recommends for ≥3 exacerbations/year.
What Pseudomonas management strategy should be covered?
Present the significance: Pseudomonas colonization is associated with 3-fold increased mortality and accelerated lung function decline. Eradication protocol at first isolation: IV anti-pseudomonal antibiotics or inhaled colistin/tobramycin for 2-4 weeks. Chronic Pseudomonas: long-term inhaled antibiotics (nebulized colistin, tobramycin, or aztreonam in 28-day on/off cycles). Reference RESPIRE 1 and 2 trials for inhaled ciprofloxacin dry powder. BSI scoring guides treatment intensity.
Simple pricing, no surprises
Start free today. Upgrade when your department needs more.
Free
Try SlideCraft with no commitment
- 2 decks per month
- AI slides with speaker notes
- View & present only (no export)
- 7-day cloud storage
- Slide Checker & Outline Generator
Pro
For clinicians who lecture weekly
- 10 decks/mo + $2.50/extra
- AI Critic Mode (5-axis review)
- Document-to-deck (PDF upload)
- PDF, PPTX, SCORM & image export
- Permanent cloud storage
Expert
For academic physicians who publish and present
- 25 decks/mo + $2.00/extra
- PubMed source verification
- Paper-to-deck pipeline
- Auto-citations (Vancouver)
- Everything in Pro